Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

Inclusion Criteria

• •Adult patients (age 18 and older) who present to rheumatology clinic
• •Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).
• •Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA
• •Participants must have a Body Mass Index (BMI) of 30kg/m\^2
• •Participants must be treated for PsA in accordance with guidelines
• •Have not achieved MDA in PsA patients
• •Have a minimum TJC \> 1 and SJC \> at baseline
• •Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.